United Kingdom - English - myHealthbox

pfizer limited - amlodipine besilate - hard capsule - 10mg - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension chronic stable angina pectoris vasospastic (prinzmetal’s) angina

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - capsules - azithromycin as dihydrate 250 mg - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin hydrochloride - capsules - clindamycin hydrochloride 150 mg - clindamycin - clindamycin - treatment of infections caused by susceptible strains of anaerobic microorganisms.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin hydrochloride - capsules - clindamycin hydrochloride 300 mg - clindamycin - clindamycin - treatment of infections caused by susceptible anaerobic bacteria.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - capsules - fluconazole 200 mg - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis.• invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.• vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.• candidal balanitis when local therapy is not appropriate.• dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.• tinea unguinium (onychomycosis) when other agents are not considered appropriate.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• to reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin hydrochloride, quantity: 177.515 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; gelatin; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia; dimeticone 1510; lecithin; ethanol; strong ammonia solution; potassium hydroxide - indications as at 20 june 2005 : dalacin c clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci - serious respiratory tract infections; serious ski

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 100 mg - capsule, hard - excipient ingredients: patent blue v; colloidal anhydrous silica; titanium dioxide; sodium lauryl sulfate; magnesium stearate; gelatin; lactose monohydrate; maize starch; erythrosine; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: patent blue v; colloidal anhydrous silica; titanium dioxide; sodium lauryl sulfate; gelatin; magnesium stearate; lactose monohydrate; maize starch; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; indigo carmine; lactose monohydrate; erythrosine; sodium lauryl sulfate; titanium dioxide; maize starch; gelatin; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; industrial methylated spirit; dimeticone 1510; lecithin - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extens

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 20 mg - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.